@article{de67d2d83a19469c916f8b0b22d28f71,
title = "Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib",
author = "Patrick Harrington and Doores, {Katie J.} and Jamie Saunders and {de Lord}, Marc and Chandan Saha and Thomas Lechmere and Hataf Khan and Lam, {Ho Pui Jeff} and Reilly, {Amy O{\textquoteright}} and Claire Woodley and Susan Asirvatham and Richard Dillon and Natalia Curto-Garcia and Sullivan, {Jennifer O{\textquoteright}} and Shahram Kordasti and Kavita Raj and Malim, {Michael H.} and Deepti Radia and Donal McLornan and Claire Harrison and {de Lavallade}, Hugues",
note = "Funding Information: PH reports research funding from Bristol Myers Squibb and speaker{\textquoteright}s fees from Incyte. DM has received speaker fees and advisory boards Novartis, Celgene and Jazz pharmaceuticals. CH has received speaker fees from Novartis, Jannsen, CTI, Celgene, Medscape and has served on the Advisory Board for Incyte, CTI, Sierra Oncology, Novartis, Celgene, Roche, AOP pharma, Geron and Astra Zenica. HdL has received research grants and honoraria from Incyte and honoraria from Novartis and Pfizer. Funding Information: Blood Cancer UK grant to PH and HdL; MPN Voice grant to PH, CH, HdL; King{\textquoteright}s Together Rapid COVID-19 Call awards to MHM, KJD; A Huo Family Foundation Award to MHM, KJD; Chronic Disease Research Foundation award CDRF-22/2020 to KJD, MHM; Wellcome Trust Investigator Award 106223/Z/14/Z to MHM; Fondation Dormeur, Vaduz for funding equipment to KJD. Mabtech, Stockholm for providing equipment to PH. ",
year = "2022",
month = apr,
day = "22",
doi = "10.1038/s41408-022-00651-3",
language = "English",
volume = "12",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "4",
}
